Item 1.01. Entry into a Material Definitive Agreement.

On September 17, 2020, Hoth Therapeutics, Inc. (the "Company") entered into a Sponsored Research Agreement (the "Agreement") with the George Washington University ("GW") effective as of September 1, 2020 (the "Effective Date"). The Agreement relates to the development of a diagnostic device for the detection of SARS-CoV-2 via a mobile device as an aid in the diagnosis of the COVID-19 infection. The Agreement commences on the Effective Date and terminates on July 31, 2021 unless such term is extended by the parties. Pursuant to the Agreement, the Company shall pay GW up to a mid six figure fee for all research costs.

The foregoing summary of the Agreement does not purport to be complete and is qualified in its entirety by reference to the Agreement which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is hereby incorporated by reference.




Item 8.01 Other Events.



The Company issued a press release on September 21, 2020 announcing the execution of the Agreement. A copy of the release is attached to this Form 8-K as Exhibit 99.1, which is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.





Exhibit No.                                 Description
10.1##          Sponsored Research Agreement by and between the Company and the George
              Washington University
99.1            Press release dated September 21, 2020

## Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions


   of this exhibit were omitted by means of marking such portions with an
   asterisk because the identified confidential portions (i) are not material and
   (ii) would be competitively harmful if publicly disclosed.




                                       1

© Edgar Online, source Glimpses